In concordance, two of our three NSCLC cell lines harbor KRAS mutations [68–70], and all CRC cell lines exhibit WNT and/or MAPK pathway alterations [71], which reflects the clinical situation [72]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.